Rifabutin Versus Rifampicin for Treatment of Staphylococcal PJI Treated With DAIR

Summary

Rifampicin, is key in the treatment of staphylococcal PJIs. Rifabutin has a better profile of tolerance than rifampicin regarding the risk of interaction with concomitant medications and liver disorders. The hypothesis is that rifabutin may be an alternative antibiotic option as efficient as rifampicin for the treatment of staphylococcal PJIs, with a better safety profile. The investigator aim to demonstrate the non-inferiority of rifabutin as compared with rifampicin prescribed in combination treatment for PJIs.

Timeline

Start

2021-11-08

Primary completion

2026-11

Completion

2027-06

Drugs

Indications